SUPRIYASupriya Lifescience Ltd.
Supriya Lifescience appoints Mangesh Vaze as chief operating officer
- Management change
- Pharmaceuticals
Reviewed byKeshav SehgalBlacklitt Research
Supriya Lifescience (NSE: SUPRIYA) has appointed Mangesh Vaze as Chief Operating Officer and Senior Management Personnel, effective 6 Nov 2026, it said in a filing on 06 Nov 2026. The board approved the appointment on the recommendation of its Nomination and Remuneration Committee.
The appointment in detail
The board of Supriya Lifescience approved the appointment of Mangesh Vaze at its meeting on 6 Nov 2026, and the appointment is effective from the same date. The filing gives no term for the appointment, which it marks as not applicable.
Vaze has a B.E. in Chemical Engineering and an Executive MBA specialised in strategy, marketing and finance. He has about 34 years of professional experience in production, process engineering, API manufacturing and operations. The filing lists earlier associations with Zydus Lifescience, Cipla, Mylan Laboratories, Apotex Pharmachem India, Wockhardt, Orchid Chemicals & Pharmaceuticals and Lupin.
How the role fits the company
Supriya Lifescience has a market value of ₹6,999 crore at the 05 Nov 2026 close of ₹869.60 a share. The appointment is made in the same board meeting that approved the company's unaudited results for the quarter and half year ended 30 Sep 2026, which the company reported on the same day.
What the appointment means for Supriya Lifescience's shareholders
The filing records a senior management appointment and makes no financial commitment that is stated in it. The filing does not say whether the role replaces an existing officer, what Vaze will be paid, or whether he will join the board as a director.
The next step the filing sets out is the effective date of 6 Nov 2026, which has already passed on the day of the filing.
At a glance
| Item | Detail |
|---|---|
| Officer | Mangesh Vaze, Chief Operating Officer and Senior Management Personnel |
| Effective date | 6 Nov 2026 |
| Term | Not applicable, per the filing |
| Recommended by | Nomination and Remuneration Committee |
| Related to a director | No, per the company |
Filed with NSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
